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Human chorionic gonadotropin (hCG) is a unique hormone produced soon after fertilization in 
women. It is an ideal target for contraception. Antibodies against hCG prevent pregnancy without 
blocking ovulation and derangement of menstrual regularity. Previous work on development of  
a vaccine against hCG is reviewed including the first ever safety and efficacy trials in women with 
a birth control vaccine. The possibility of a recombinant vaccine with enhanced immunogenicity is 
indicated. 
 
Keywords: Efficacy, human chorionic gonadotropin, recombinant vaccine, safety. 
 
THE population of the world is continuing to grow and is 
projected to reach 7 billion by 2012, according to the 
2008 revision of the official United Nations population 
estimates and projections (UN Population Division/ 
DESA). India has a population of 1.16 billion and it is 
growing at the rate of 1.548% (15.5 millions per year  
according to 2009 estimate) every year, which is roughly 
equal to the entire population of Australia. This many  
extra numbers pose demands for food, water, education 
and jobs. India has 2.4% of geographical area of the 
world, whereas its population is 15% of the world’s 
population. We are already about six times over popu-
lated. Leave aside land, water essential for life and agri-
culture is becoming scarce day by day. Although efforts 
are being made to harness water resources and enhance 
productivity of the land, there is need to limit the size of 
the family voluntarily by providing safe and acceptable 
methods for family planning. 
 Currently, the methods available for contraception are 
many. However these are not used by those in need for 
various reasons. The most dependable single time inter-
ventions are tubal ligation for women and vasal ligation 
for men. In spite of incentives, these are resorted to fairly 
late in the reproductive life of the couple after engender-
ing many children. Intrauterine devices (IUDs) entail  
extra bleeding; Indian women who are already anaemic 
cannot support it for long. Spermicides increase the effec-
tiveness of certain barrier methods of contraception such 
as diaphragm. However, they do not provide reliable con-
traception when used alone1. Steroidal contraceptives in 
form of pills, injectibles and implants are highly effective 
but they have side effects varying from weight gain2,  
decrease in bone mineral density (BMD)3 spotting and 
derangement of menstrual regularity and bleeding pro-
files. Condoms bring in besides contraception extra safety 
against transmission of human immunodeficiency virus 
(HIV) and sexually transmitted diseases (STD), but in 
spite of wide publicity for ‘safe sex’, their use is still not 
widespread nor consistent. With this background, addi-
tional methods are required as options for family plan-
ning, specially those that do not require day-to-day 
motivation, are reversible and do not derange menstrual 
profiles nor entail extra bleeding. It is in this context that 
work was initiated many years ago to develop a potential 
birth control vaccine based on eliciting antibodies inacti-
vating human chorionic gonadotropin (hCG). A safe,  
effective and reversible birth control vaccine would be a 
valuable addition to the currently available fertility-
regulation methods. 
Role of hCG 
The choice of hCG as target was based on the rationale 
that it comes into play only when the embryo reaches the 
endometrium. No hCG is secreted by the pituitary. Folli-
cle stimulating hormone (FSH), lutenizing hormone (LH) 
are the gonadotropins made and secreted by pituitary. 
They travel to the ovaries to develop follicles, secrete  
estradiol and progesterone and induce ovulation. Anti-
bodies against hCG would not intervene in this axis and 
women would keep on ovulating and normally producing 
their sex hormones. It may be recalled that the steroidal 
contraceptives employed in the pills, injectibles and  
implants inhibit the hypothalamic–pituitary gonad axis. 
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They block the secretion of FSH and LH thereby block-
ing ovulation and normal estradiol and progesterone pro-
duction. 
 The synthesis of hCG starts soon after fertilization of 
the egg. Eggs fertilized in vitro by assisted reproductive 
technology secrete hCG in the culture medium4 before 
embryo is transferred to the uterus. The hCG secreted at 
this stage is critical to implantation, which leads to the 
onset of pregnancy. Antibodies neutralizing the bioacti-
vity of hCG prevent the establishment of pregnancy. The 
role of hCG in implantation is supported by observations 
in primates as well as in humans. Marmoset embryos  
exposed to antibodies against hCG fail to implant, whereas 
those exposed to normal immunoglobulins implant nor-
mally5. The prevention of implantation by antibodies 
against hCG is also evident from the observations in 
women immunized with a vaccine against hCG. Whereas 
circulating antibodies against hCG above the protective 
threshold prevented pregnancy in sexually active women, 
no lengthening of the luteal phase was observed in them6. 
They continued to ovulate normally and had regular men-
strual cycles. Had the antibodies been acting as abortifa-
cients post-implantation, the length of the luteal phase 
would have been longer and menstruation more copious. 
This was not the case in trials conducted in women. Thus 
the vaccine by generating antibodies neutralizing the bio-
activity of hCG prevents the nidation or implantation of 
the embryo and thereby the establishment of pregnancy. 
No effect is exercised on the hypothalamic-pituitary  
gonad axis. Hence, neither ovulation is impaired nor the 
synthesis by the women of natural sex steroids. 
Rendering hCG immunogenic 
The mother and as the foetus are exposed to high levels 
of hCG during pregnancy; hence both are immunologi-
cally tolerant to this hormone. To make it immunogenic, 
it was conjugated to a carrier mobilizing the T-cell help. 
The carrier selected initially was tetanus toxoid (TT). In 
the 1970s, a large number of women used to die of teta-
nus by infection contracted during delivery taking place 
at home or in the field7. The use of tetanus as carrier was 
aimed to accomplish two purposes; to override the immu-
nological tolerance against hCG as well as to induce anti-
body response against tetanus thereby preventing post-
delivery deaths due to this infection. 
 The hCG is a heterodimer of two subunits α and β; α is 
common to three other pituitary hormones, viz. h-thyroid 
stimulating hormone (hTSH), hFSH, hLH. The β subunit 
in each case confers the hormonal identity. Hence, hCGβ 
instead of the whole hCG was chosen as antigen with the 
hope that its linkage with TT would induce antibodies  
reacting with hCG and not with other pituitary hormones 
containing the common α subunits. This was indeed 
found to be the case8,9. Furthermore, sera from three 
women immunized with hCGβ-TT showed no reaction 
with human thyroid, pituitary, parathyroid, adrenal, testes 
and ovaries as examined by immunohistochemical tech-
niques10. hCGβ-TT vaccine not only generated hCG  
neutralizing antibodies in rodents and monkeys11 but also 
in four women immunized with this vaccine in a probing 
clinical trial conducted after thorough reversibility and 
safety studies12. Anti-hCG response was obtained in all 
women along with the antibodies reacting against TT. 
Figure 1 a recalls the pertinent findings. The duration of 
antibody response in subject ND was 500 days. 
 Whether the antibodies thus generated recognize in 
vivo hCG or not, was tested by challenge with two dou-
bling doses of hCG. Purified authentic hCG administered 
to immunized women bound to the circulating antibodies, 
 
 
 
 
Figure 1. a, Time kinetics of anti-hCG and anti-tetanus antibody  
response in subject ND immunized with four injections of hCGβ-TT at 
fortnightly intervals (adapted from Talwar et al.12). b, Anti-hCG and 
anti-tetanus toxoid titres in the subject ND after injection of 2000 and 
4000 IU of hCG. Circulating antibodies bound with the administered 
hCG causing decline of titers, which in course of time returned to the 
same level as at the time of challenge. No effect of hCG was seen on 
anti-tetanus titres (adapted from Ramakrishnan et al.57). 
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causing a decline of the antibody levels (Figure 1 b). hCG 
alone did not act as booster, the titres came back to the 
normal range in course of time. Thus, the immunization 
strategy employed could not be expected to cause an  
internal auto-boosting every time hCG is secreted by 
women in fertile cycles. This deduction is supported by 
Phases I and II clinical trials conducted by us in 253 
women6,13,14. Interestingly, the administered hCG did not 
cause any change in the anti-TT titres confirming that the 
vaccine was generating antibodies independently against 
both hCGβ and TT. 
hCGβ versus carboxy terminal peptide 
hCGβ shares 85% homology with hLHβ. The hCGβ how-
ever has an additional 35 amino acid carboxy terminal  
peptide (CTP), which is not present in hLHβ. On basis of 
its presence in hCGβ and not in hLHβ, the logic was to 
employ the CTP instead of the entire hCGβ as an immu-
nogen. Vernon Stevens and the World Health Organiza-
tion (WHO) Task Force in fact chose the CTP15 for 
developing an anti-hCG vaccine. We however decided to 
use the entire hCGβ on the following grounds. 
 
• hCGβ was much more immunogenic than CTP, which 
obligatorily demanded the use of strong oily adjuvants 
before any antibody is detectable15. In contrast, hCGβ-
TT was immunogenic with alum as adjuvant which is 
permitted for human use by the drugs regulatory  
authorities in India and elsewhere. 
• The avidity of the antibodies induced by CTP vaccine 
was two logs lower than that induced by the hCGβ-TT 
(Ka 108 versus Ka 1010 M–1). In view of the reported 
high affinity of hCG for its receptor (Ka 109 M–1), it 
was our belief that the antibodies elicited by the CTP 
vaccine would have low bioneutralization capacity. In 
fact, data is not available on the ratio of hCG bioneu-
tralization capacity and binding capacity index (B/I) of 
the CTP-TT antibodies, whereas more than one labora-
tory has confirmed the bioneutralization ability of the 
antibodies generated by the vaccines employing the 
entire hCGβ-TT16. Table 1 summarizes the properties 
of these vaccines. 
 
 The expected advantage of using CTP as immunogen 
was only partially realized. The anti-CTP antibodies were 
no doubt nonreactive with hLH. However, much to the 
consternation of all, these antibodies reacted with soma-
tostatin producing cells of pancreas and pituitary, 
whereas the sera generated by hCGβ-TT and HSD-
TT/DT vaccines did not have such cross-reaction17. This 
was presumably due to the fact that the CTP vaccine  
generates predominantly sequence reading antibodies, 
whereas the hCGβ vaccine elicits predominantly confor-
mation reading antibodies. 
 The CTP vaccine of Stevens given with strong oil-
based adjuvants was withdrawn during clinical trials in 
Sweden, when it produced unacceptable reactions in the 
first seven women immunized with it. The WHO task 
force ascribed the reactions to the instability of the adju-
vant. No further trials have however taken place with the 
CTP vaccine till now, nor any paper published on the 
subject. 
Reversibility and safety clinical trials 
The International Committee on Contraception Research 
(ICCR) of the Population Council, New York carried out 
a Phase I safety trial on our hCGβ-TT vaccine with the 
approval of the US Food and Drug Administration (FDA) 
and other agencies in Finland, Brazil, Chile and Sweden. 
The findings confirmed not only the safety but also the 
reversibility of the hCGβ-TT vaccine18. Women conti-
nued to have regular menstrual cycles and had normal  
levels of gonadotropins and sex steroids after vaccination. 
The antibodies neutralized hCG bioactivity in in vitro  
assays. 
 
 
Table 1. Comparative properties of antibodies generated by the three vaccines formulated against human chorionic  
 gonadotropin 
 Immunogen (adjuvant and vehicle) 
 
 CTP-DTa β hCG-TTb HSD-TT/DTc  
 (Squalene, MPD, Arlacel A) (Alum) (alum + SPLPS) 
 
Peak titre (ng/ml) 36–127 120–1800 222–6000 
Avidity (M–1)d 108 1010 1010 
B/I indexe ? 52 61 
Cross-reactivity with hTSH and hFSH – – – 
hLH – + + 
Pancreatic cells +f – – 
aFrom Jones et al.52. bFrom Thau et al.55. cFrom Om Singh et al.16. dAvidity data from collaborative studies. 
eB/I (bioneutralization capacity/antigen binding capacity) index data from Talwar and Singh56. fData from Rose  
et al.17. 
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How hazardous would the cross reaction with 
hLH be? 
The tonic levels of hLH are low throughout the menstrual 
cycle, but a surge occurs as a peak in the midcycle caus-
ing ovulation. The fact that women immunized with 
hCGβ-TT vaccine in India and in other countries contin-
ued to ovulate indicates that the partial cross-reaction 
with hLH of the antibodies induced by the vaccine did 
not reduce the levels of hLH below the threshold required 
for inducing ovulation. Nonetheless, sustained cross-
reaction with LH over prolonged periods could be detri-
mental. Also, the antigen–antibody complexes formed as 
a result of this cross-reaction may get deposited in the 
kidney, pituitary or the ovaries causing pathological 
problems. To seek answers to these natural queries, Shel-
don Segal planned a long-term study (5–7 years) at the 
Population Council which was conducted in 63 rhesus 
monkeys. They were immunized with ovine LHβ (oLHβ), 
inducing antibodies frankly cross-reacting with monkey 
LH (RhLH). Although the cross-reaction of the oLHβ  
antibodies with RhLH was significant, the females conti-
nued to ovulate and had regular menstrual cycles. Histo-
pathological examinations were carried out on the ovary 
and pituitary of 48 of the 63 immunized monkeys. There 
was no difference between the pituitaries of immunized 
and non-immunized animals19. Systematic toxicology20 
evaluation in comparison with age-matched controls was 
carried out in 10 of these animals. Neither the gross  
pathology, nor the organ weights revealed evidence of  
adverse side-effects of immunization. Studies on the  
effects of immunization on atherosclerotic lesions, and 
coronary and carotid arteries and in the aorta showed no 
differences between immunized and control monkeys 
with respect to the arterial characteristics (plaque area, 
maximal plaque thickness, per cent lesions and per cent 
stenosis) that were used as indicators of the extent and/or 
severity of atherosclerosis21. Thus, the antibodies with 
variable degree of cross-reaction with LH in either mon-
keys or in women did not reduce LH below the critical 
amount required to induce ovulation (being given that the 
surge has surplus levels of LH). Long-term (five years) 
toxicology in monkeys did not put in evidence damage of 
any tissue due to possible immune complexes. 
hCG auto-antibodies 
The occurrence of auto-antibodies to hCG is a rare pheno-
menon. In the literature only two female cases have been 
reported. One of these was a patient with nine years his-
tory of secondary infertility22. She had a normal preg-
nancy at the age of 16 years with normal vaginal 
delivery. After three years of contraception, the patient 
tried for several years to become pregnant. She had regu-
lar menstrual cycles and was shown to be ovulating but 
experienced recurrent pregnancy loss. On thorough inves-
tigations, it was found that she had auto-antibodies to 
hCG which had low affinity (Ka 1.4 × 106 l/mol), but 
high capacity (418 nmol/l) for hCG. The circulating anti-
bodies had low cross-reaction with recombinant hFSH, 
recombinant human LH, hCGα and hCGβ (< 0.019%, 
0.021%, 0.039% and 0.006%) respectively, but prevented 
the whole dimer hormone hCG action on establishment 
and sustenance of pregnancy22. 
 The second case reported in the literature is of a 32-
year-old woman, whose infertility was zeroed into circu-
lating antibodies against hCG23. No clear understanding 
is available on how these women developed auto-
antibodies to hCG. These ‘experiments of Nature’ in a 
way confirm the anti-fertility action of antibodies against 
hCG. They further showed that though such antibodies 
prevent pregnancy, they do not interfere with ovulation 
and normal menstrual regularity. 
 Johnson et al.24 examined a large group of infertile 
women, none of them carried antibodies against hCG or 
other trophoblast products. Besides these two women, 
four male patients have been reported25. They were hypo-
gonadotropic, hypogonadic and they developed low affinity 
anti-hCG antibodies on long-term treatment with exoge-
nous urinary derived hCG. 
hCGβ based vaccine 
hCGβ has to link with α subunit to trigger the hormonal 
response. It is the dimer and not the α or β subunits indi-
vidually that exercise biological activity. While linking 
with the homologous human α subunit was contraindi-
cated in view of its identity with α subunit of hTSH, 
hFSH, hLH, we thought of creating a heterospecies dimer 
(HSD) by joining non-covalently hCGβ with α ovine 
subunit. The ability of subunits to link is conserved 
across species in mammals. Ovine LHα (oLHα) can  
intrinsically link with hCGβ to generate HSD. The dimer, 
HSD, fully recognized the hCG receptor and even evoked 
a better steroidogenic response than hCG26. Furthermore, 
conjugates of HSD with TT had better immunogenicity in 
rats and bonnet monkeys, and the antibodies had a better 
capacity for neutralization of the bioactivity of hCG9. 
None of the immunized sera was reactive with hFSH and 
hTSH as determined by binding with radio-iodinated 
hormones9. 
Phase I safety trials 
After due preclinical toxicology studies and permissions 
from the Drugs Controller General of India and Institu-
tional Ethics Committees, comparative Phase I clinical 
trials with the hCGβ-TT and HSD-TT vaccines were con-
ducted in five centres in India under the auspices of the 
Indian Council of Medical Research (ICMR). All women 
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immunized with these vaccines generated anti-hCG and 
anti-TT antibodies. Clinical examinations were carried 
out at intervals of 4–6 weeks. The cycles were ovulatory 
and menstrual regularity was unaffected13. Immunization 
with these formulations had no significant effect on hae-
matological, clinical chemistry and other metabolic  
parameters14. The bioneutralization capacities of antibod-
ies generated by the heterospecies dimer-TT vaccine were 
25% higher on an average than those generated by hCGβ-
TT27. On repeated immunization with TT as carrier, few 
subjects demonstrated suppression of antibody response 
against hCG due to carrier-induced epitope specific-
suppression28, which could be overcome by immunization 
with an alternate carrier such as diphtheria toxoid (DT) or 
cholera toxin chain B (CTB)29. Subjects immunized with 
formulation HSD-TT gave a more consistent antibody re-
sponse (with not as much variation amongst individuals) 
and the mean duration of the antibody titres was better in 
subjects immunized with HSD-TT compared to hCGβ-TT. 
Phase II efficacy trials with HSD-hCG vaccine 
These were the first ever efficacy trials conducted with 
any birth control vaccine in women6. About 148 women 
of proven fertility with two living children were enrolled 
in the trial. All enrolled women were sexually active and 
hyperfertile. Many had come to the investigating institu-
tions, the All India Institute of Medical Sciences (AIIMS, 
New Delhi), Post Graduate Institute of Medical Educa-
tion and Research (PGIMER, Chandigarh) and Safdar-
jung Hospital, New Delhi, for medical termination of 
pregnancy. The available methods for family planning  
either did not suit these women or were not used consis-
tently. 
 All women generated antibodies against hCG. No 
pregnancy took place in the women at and above 50 ng/ 
ml titres bioneutralization capacity. About 119 (80%) had 
titres above 50 ng/ml bioneutralization capacity. How-
ever, only 60% women maintained antibody titres above 
50 ng/ml threshold for three months or longer. All women 
continued to have regular menstrual cycles and had luteal 
progesterone indicative of normal ovulation. The anti-
body titres declined with time but booster injections 
raised the levels (Figure 2). Eight women completed 
more than 30 cycles by voluntary intake of boosters with-
out becoming pregnant, nine completed 24–29 cycles, 12  
completed 18–23 cycles, 15 completed 12–17 cycles and 
21 subjects completed 6–11 cycles. Women became read-
ily pregnant in absence of boosters on antibodies declin- 
 
 
 
Figure 2. Kinetics of anti-hCG response in four subjects (MRG, HJN, TRW, SVN) after immunization with the 
HSD vaccine. All subjects were of proven fertility with two live children (P2); HJN and SVN had also undergone 
elective termination of an unwanted pregnancy (P2+1). Square at the top edge of the figure denote menstrual events, 
which were by and large regular and of normal duration. Solid horizontal lines denote the period during which these 
women were exposed to possible pregnancy with no alternate contraceptive used. Arrows denote injections of the 
vaccine at a gonadotropin dose of 300 μg (adapted from Talwar et al.6). 
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ing to 35 ng/ml or lower levels. Figure 3 is a typical rep-
resentation. The subject STS with two children and one 
medical termination of pregnancy was protected from  
becoming pregnant for 450 days. She became pregnant in 
the immediate cycle in which antibody titres fell below 
35 ng/ml. 
 The efficacy of the vaccine to prevent pregnancy was 
high with only one pregnancy recorded in 1224 cycles 
above 50 ng/ml (refs 6 and 30). The vaccine was well  
tolerated. The response to the vaccine was reversible;  
antibody titres declined in all subjects in the absence of 
booster injections. 
 These historic trials provided hard evidence on the 
ability of circulating anti-hCG antibodies to prevent 
pregnancy without impairment of ovulation and without 
derangement of menstrual regularity and bleeding  
profiles. These also indicated 50 ng/ml bioneutralization  
capacity as protective threshold titres. Women regained 
fertility readily as and when titres declined below 
35 ng/ml. No short- or long-term adverse effects of  
immunization were observed. Progeny born to pre- 
viously immunized women had normal developmental  
landmarks and cognitive abilities compared to their sib-
lings31. 
 The only shortcoming of this vaccine was the induction 
of above 50 ng/ml titres in only 60–80% of the women, 
which would be considered as adequate for a vaccine 
against infections but for fertility control, efficacy above 
90% is required and desirable. Thus, immunogenicity of 
the vaccine had to be improved to make this candidate 
vaccine practicable for fertility control. 
 
 
 
 
Figure 3. Regain of fertility on decline of antibodies. A 30-year-old 
subject with two gravidae and one elective abortion (P2+1), on immuni-
zation with the vaccine, remained protected from pregnancy for 12  
cycles. In the absence of booster injection, antibody titres declined and 
she became pregnant in the cycle starting on day 417 (adapted from 
Talwar et al.6). 
Revival of the hCG vaccine 
R&D on the hCG vaccine was revived under an Indo-US 
programme with a grant from the Department of Biotech-
nology in 2006. This enabled the making of a recombi-
nant vaccine consisting of hCGβ linked at C-terminal to 
B subunit of heat labile enterotoxin of E. coli (Figure 4). 
The engineered construct has been expressed in Pichia 
pastoris with good yield, rendering it amenable to indus-
trial production at low cost. The vaccine adsorbed on just 
alum, a permitted adjuvant for human use, has generated 
antibody titres well above 50 ng/ml in every BALB/c 
mouse immunized with it. Studies in mice of five inbred 
strains of different genetic background, encompassing 
haplotypes H-2d, H-2k, H-2b, H-2s, H-2q confirm the posi-
tivity of response with this vaccine in all animals. Inclu-
sion of an adjuvant Mycobacterium indicus pranii32 (MIP, 
previously Mw), which is approved by the Drugs Con-
troller General of India and USFDA as an immuno-
therapeutic vaccine against leprosy, has further enhanced 
the antibody titres to as high as 6500 ng/ml in BALB/c 
mice. Mw was incidentally developed by Talwar et al.33,34 
as an immunotherapeutic vaccine for multi-bacillary lep-
rosy. Employed as an adjunct to standard chemotherapy, 
it expedites the clearance of bacilli and clinical recovery 
of patients34,35. MIP shares antigens with both Mycobac-
terium leprae and Mycobacterium tuberculosis. It is a po-
tent stimulator of IL-12 and IFN-γ. This remarkable 
adjuvant brings in additional attributes to the vaccine. 
Ongoing work by Dipankar Nandi at the Indian Institute 
of Science, Bangalore indicates preventive and therapeu- 
 
 
 
 
Figure 4. The new recombinant anti-hCG vaccine hCGβ–LTB induc-
ing antibodies in every mouse at several fold higher titres than 
50 ng/ml. The carrier LTB (according to Salmond et al.54) is linked at  
C-terminal amino acid glutamine of hCGβ unit (according to Lapthorn  
et al.53). 
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tic action of Mw against two cancers tested in mice. Stud-
ies by Om Singh at the National Institute of Immunology, 
New Delhi show the therapeutic action of the hCGβ-TT 
vaccine plus Mw in hCG synthesizing tumours. Of late, 
many reports have appeared on the ectopic or unexpected 
expression of hCG/hCGβ by a variety of cancers like 
lung36, bladder37, colon38, gastric39,40, pancreatic41, breast42, 
cervical43, oral44,45, head and neck46, vulva/vaginal47,48, 
prostate49 and renal cancers50,51. Detection of hCGβ  
expression in tumours is usually associated with poor 
prognosis and adverse survival33,47. Thus a safe vaccine 
generating high titre bioeffective antibodies may find  
additional utility in treatment of advanced stage cancers 
expressing hCG/hCGβ. 
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